311.92

5.86% 17.27

After Hours: 311.92

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $311.92, with a volume of 352.74K. It is up +5.86% in the last 24 hours and down -10.25% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Previous Close:

$294.65

Open:

$296.81

24h Volume:

352.74K

Relative Volume:

0.70

Market Cap:

$8.69B

Revenue:

$7.46M

Net Income/Loss:

$-303.27M

P/E Ratio:

-23.16

EPS:

-13.4668

Net Cash Flow:

$-249.12M

1W Performance:

+8.01%

1M Performance:

-10.25%

6M Performance:

+533.34%

1Y Performance:

+769.83%

1-Day Range:

$296.81

$314.00

1-Week Range:

$285.00

$314.00

52-Week Range:

$26.70

$356.00

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

10,998

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	311.92	8.21B	7.46M	-303.27M	-249.12M	-13.47
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Feb-02-26	Initiated	Wells Fargo	Equal Weight
Dec-15-25	Reiterated	Oppenheimer	Outperform
Nov-19-25	Initiated	BTIG Research	Buy
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

Mar 25, 2026

Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN

Mar 25, 2026

Mar 23, 2026

(PRAX) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Mar 23, 2026

Mar 22, 2026

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - AOL.com

Mar 22, 2026

Mar 21, 2026

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - AOL.com

Mar 21, 2026

Aug Swings: Is Praxis Precision Medicines Inc forming bullish engulfing patterns2026 Reactions & Reliable Momentum Entry Alerts - baoquankhu1.vn

Mar 21, 2026

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline - AOL.com

Mar 21, 2026

Mar 18, 2026

5AM Venture Divests Entire Praxis Precision Medicines Position | February 2026 FilingNews and Statistics - IndexBox

Mar 18, 2026

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit - Yahoo Finance

Mar 18, 2026

Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? - Yahoo Finance

Mar 18, 2026

Mar 17, 2026

Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway - Insider Monkey

Mar 17, 2026

PRAX PE Ratio & Valuation, Is PRAX Overvalued - Intellectia AI

Mar 17, 2026

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - AOL.com

Mar 17, 2026

Algert Global LLC Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Mar 17, 2026

Mar 16, 2026

Cormorant Sells $9.31M in Praxis Shares, Holding Remains Top Position | 2026 UpdateNews and Statistics - IndexBox

Mar 16, 2026

This biotech stock, which has surged by 700%, remains one of the leading holdings even after a $9.3 million sale in the previous quarter. - Bitget

Mar 16, 2026

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool

Mar 16, 2026

HighVista Strategies LLC Has $5.04 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Mar 16, 2026

Mar 15, 2026

Praxis Precision Medicines (PRAX) Is Down 5.4% After Major Institutional Buying and FDA FilingsHas The Bull Case Changed? - simplywall.st

Mar 15, 2026

Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? - Yahoo Finance

Mar 15, 2026

Mar 14, 2026

Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue - Yahoo Finance

Mar 14, 2026

PRAX Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 14, 2026